Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics.

Biotechnology

Celularity

Dr. Bob Hariri is an accomplished surgeon, biomedical scientist, and serial entrepreneur in two technology sectors, biomedicine and aerospace.

He is the chairman, founder, and chief executive officer of Celularity, Inc., one of the world’s leading human cellular therapeutics companies.

Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics

Robert J Hariri

Mark Awadalla is the current Vice President of Clinical R&D and Head of Clinical Operations at [Celularity](/org/celularity). Prior to this, they served as the Senior Director of Clinical Operations at [Mustang Bio](/org/mustang-bio) from January 2018 to September 2020. Before that, they were the Global Clinical Trials Manager at Celgene from May 2007 to May 2016. In this role, they managed global phase II and III clinical trials and provided leadership guidance for on-time deliveries of key milestones. Mark has also worked as the Senior Global Clinical Project Manager at Cmed Clinical Services from September 2005 to May 2007, where they directed cross-functional teams for all sponsor deliveries and contracted responsibilities. In addition, they have served as the Director of Clinical Development at Lion Biotechnologies, Inc. from May 2016 to January 2017 and as a Contract Consultant Clinical Research Manager at various consulting firms from August 2001 to September 2005.

Mark Awadalla completed their undergraduate studies at Stockton University, where they majored in biochemistry and molecular biology.

Mark Awadalla works with Bradley Glover - CTO, Anne Jones - Chief Business Officer, and Sharmila Koppisetti - VP, Drug Safety Pharmacovigilance. Their manager is Robert J Hariri, Chairman, Founder & CEO.

Mark Awadalla

Dr. Glover is responsible for leading all aspects of [Celularity](/org/celularity)’s technical operations, including process development, quality, manufacturing, supply chain, IT, facilities and engineering, and strategy and business operations for commercial products and clinical pipeline programs.

Dr. Glover joined [Celularity](/org/celularity) from Kite Pharma, where he has held several executive roles in Corporate Development and Technical Operations and was responsible for the strategic oversight and leadership of corporate strategy, corporate program and portfolio management, technical operations strategy, CMC program management and business operations. Prior to this position, he held multiple senior roles of increasing responsibility at [Genentech](/org/genentech) and Roche, including positions in Alliance Management, Strategy, Finance and was the head of the business and supply chain operations at the Oceanside biologics facility.

Earlier in his career, Dr. Glover held a number of additional senior roles at a variety of companies, including Biosite, Amgen Ventures and [Illumina](/org/illumina).

Dr. Glover earned his Bachelor of Science in biochemistry from the University of California San Diego (UCSD), his doctorate from the University of Colorado in biochemistry and molecular genetics and an MBA from the Rady School of Management at UCSD. He was also a Jane Coffin Childs Medical Research Fellow at the University of California Berkeley.

Bradley Glover

Adrian Kilcoyne

Shawn He

William Van Der Touw

Tim Wilk

Anna Gosiewska

Jay Bloom is currently a board member at [Celularity](/org/celularity). Prior to that, they worked as a Senior Vice President at [Bank of America](/org/bank-of-america) from November 2008 to March 2016. In this role, they managed a team of 35-60 employees in seven US locations that supported the back office processing platform for US Trust. Jay was also responsible for setting priorities, allocating resources, managing the budget, partnering with business users to define requirements and priorities, and monitoring projects progress. From April 2016 to December 2016, Jay worked as a Partner/Senior Management Consultant at Metro Solutions Inc. In this role, they provided program and project management, business guidance, and problem solving for First Niagara Indirect Auto business integration with Key Bank. Jay also uncovered and removed program road blocks, documented and designed processes for post implementation, managed multiple work streams to work together to meet deadlines, and managed external vendors.

Jay Bloom has a MBA in Finance from NYU Stern School of Business, a B.S. in Computer Science from Brooklyn College, and is certified in Acing Your Interview and Agile Project Management from [LinkedIn](/org/linkedin).

Jay Bloom

David Beers is the current Chief Financial Officer at [Celularity](/org/celularity). Prior to joining [Celularity](/org/celularity), David spent 9 years at Goldman Sachs Asset Management where they were a Portfolio Manager for the Goldman Sachs Income Builder Fund and Real Estate Balanced Fund, as well as a member of the High Yield Team. David has also worked as a Vice President of High Yield at T Rowe Price. David has extensive experience in the financial sector and is an expert in high yield investments.

David Beers studied East Asian Studies at [Princeton University](/org/princeton) and then went on to study finance at The Wharton School, where they earned their Master of Business Administration (MBA).

They work with Anne Jones - Chief Business Officer, Andrew L. Pecora - President, and John Haines - EVP & Chief Operating Officer. David Beers reports to Robert J Hariri, Chairman, Founder & CEO.

David Beers

Louis Weiner

John Colerangle is currently the Director of Regulatory Affairs at [Celularity](/org/celularity). Prior to this, they worked as an Associate Director for Global Regulatory Affairs at Sanofi U. S. Inc. from May 2010 to September 2019. John has also worked as a Regulatory Toxicologist at the United States Food and Drug Administration from July 1999 to August 2007. In this role, they were responsible for providing scientific interpretation of all nonclinical PK/PD and safety data to ensure safety for human exposure and outlining potential risk(s). John also authored nonclinical sections of regulatory submissions including investigator brochure, IND, NDA, Annual Reports, and product labels.

John Colerangle received their Ph.D. in Toxicology from the [University of Alabama at Birmingham](/org/university-of-alabama-at-birmingham) and their DVM in Veterinary Medicine from [Tuskegee University](/org/tuskegee-university). John is certified by the American Board of Toxicology, Inc. in DABT and by the American Board of Toxicology in Diplomate, American Board of Toxicology (DABT). John is also certified by the Regulatory Affairs Professional Society in Regulatory Affairs Certified (RAC).

Some of their coworkers include Cherie Daly - VP, Medical Affairs, Anne Jones - Chief Business Officer, and Stephen Brigido - President, Degenerative Diseases. Their manager is Robert J Hariri, Chairman, Founder & CEO.

John Colerangle

carlos ramirez

John Haines

Anne Jones

Dean Kehler

Marc Mazur is a board member at [Celularity](/org/celularity). Marc has also served on the boards of [BrightStar Care](/org/brightstar-care), Brightwood Capital, GSV Asset Management, and Brevan Howard. In addition to their board work, Mazur has also been a director at DeVilbiss Healthcare and [StayWell](/org/staywell).

Marc Mazur received their Bachelor's degree from [Columbia College](/org/columbia-college) (NY) and then went on to get their Doctor of Law - JD from Villanova University Charles Widger School of Law.

Marc Mazur

Sharmila Koppisetti

Cherie Daly

Peter H. Diamandis

Keary Dunn

Hematology/Oncologist, Scripps Green Hospital, The Scripps Cancer Research Institute

Darren Sigal

Lim Kok

Former CEO of Apple Inc
Former President of Pepis-Cola

John Sculley

Founder & Chair, Stem for Life Foundation and Cura Foundation

Robin Smith

Former FDA Commissioner
Former Director National Cancer Institute

Andrew Von Eschenbach

Beth Steinbrenner

Stephen Brigido

The current leadership team at Celularity has a wide range of experience in finance, asset management, regulatory affairs, pharmacology and toxicology, clinical operations, and biochemistry. They also hold degrees from some of the most prestigious schools in the country, including The Wharton School, Princeton University, and the University of Alabama at Birmingham. This team is well-equipped to handle the challenges of running a successful biotech company.

Leadership Team

About

Team members

Other teams at Celularity

Board of Directors

CEO and Executive Team

Discover similar companies